BANK VONTOBEL/CALL/ROCHE GS/230/0.1/20.09.24 Stock

Warrant

DE000VM4KE87

Delayed Deutsche Boerse AG 07:53:21 2024-06-27 EDT
2.49 EUR +3.32% Intraday chart for BANK VONTOBEL/CALL/ROCHE GS/230/0.1/20.09.24
Current month+127.36%
1 month+127.36%
Date Price Change
24-06-27 2.49 +3.32%
24-06-26 2.41 -15.44%
24-06-25 2.85 -1.38%
24-06-24 2.89 +4.71%
24-06-21 2.76 +13.11%

Delayed Quote Deutsche Boerse AG

Last update June 27, 2024 at 07:53 am

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying ROCHE HOLDING AG
IssuerLogo Issuer Vontobel Vontobel
WKN VM4KE8
ISINDE000VM4KE87
Date issued 2023-10-24
Strike 230 CHF
Maturity 2024-09-20 (85 Days)
Parity 10 : 1
Emission price 1.84
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 3.24
Lowest since issue 0.46
Delta0.83x
Omega 8.660
Premium1.27x
Gearing10.46x
Moneyness 1.090
Difference Strike -20.35 CHF
Difference Strike %-8.85%
Spread 0.01
Spread %0.40%
Intrinsic value 2.153

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
249.6 CHF
Average target price
278.1 CHF
Spread / Average Target
+11.40%
Consensus